[
  {
    "ts": null,
    "headline": "Amgen : Advancement in Combination Biomarker Driven Therapy for Adult Patients with Chemorefractory KRAS G12C Mutated Metastatic Colorectal Cancer (mCRC)",
    "summary": "Colorectal cancer is the third leading cause of cancer-related deaths in the United States.1 There is a critical need for more effective treatment options for patients with CRC, particularly for...",
    "url": "https://finnhub.io/api/news?id=5eebf267f3c6154fbffcebd120dc9075573fac8c0e856490e892d486654a5ee7",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1737113224,
      "headline": "Amgen : Advancement in Combination Biomarker Driven Therapy for Adult Patients with Chemorefractory KRAS G12C Mutated Metastatic Colorectal Cancer (mCRC)",
      "id": 132415561,
      "image": "",
      "related": "AMGN",
      "source": "Finnhub",
      "summary": "Colorectal cancer is the third leading cause of cancer-related deaths in the United States.1 There is a critical need for more effective treatment options for patients with CRC, particularly for...",
      "url": "https://finnhub.io/api/news?id=5eebf267f3c6154fbffcebd120dc9075573fac8c0e856490e892d486654a5ee7"
    }
  },
  {
    "ts": null,
    "headline": "FDA APPROVES LUMAKRAS速 (SOTORASIB) IN COMBINATION WITH VECTIBIX速 (PANITUMUMAB) FOR CHEMOREFRACTORY KRAS G12C-MUTATED METASTATIC COLORECTAL CANCER",
    "summary": "Pivotal Study Demonstrated the Combination More Than Doubled Progression-Free Survival Compared to Investigated SOCTHOUSAND OAKS, Calif., Jan. 17, 2025 /PRNewswire/ -- Amgen today announced that the...",
    "url": "https://finnhub.io/api/news?id=162057ce328657abad1039a15325635ad46eaa6a9658b9788d9b457f1d6f442a",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1737104525,
      "headline": "FDA APPROVES LUMAKRAS速 (SOTORASIB) IN COMBINATION WITH VECTIBIX速 (PANITUMUMAB) FOR CHEMOREFRACTORY KRAS G12C-MUTATED METASTATIC COLORECTAL CANCER",
      "id": 132414916,
      "image": "",
      "related": "AMGN",
      "source": "Finnhub",
      "summary": "Pivotal Study Demonstrated the Combination More Than Doubled Progression-Free Survival Compared to Investigated SOCTHOUSAND OAKS, Calif., Jan. 17, 2025 /PRNewswire/ -- Amgen today announced that the...",
      "url": "https://finnhub.io/api/news?id=162057ce328657abad1039a15325635ad46eaa6a9658b9788d9b457f1d6f442a"
    }
  }
]